about
Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6Metabolism, toxicity and anticancer activities of arsenic compounds.Mechanisms underlying the inhibitory effects of arsenic compounds on protein tyrosine phosphatase (PTP).Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradationDisruption of the arsenic (+3 oxidation state) methyltransferase gene in the mouse alters the phenotype for methylation of arsenic and affects distribution and retention of orally administered arsenate.Phenylarsine Oxide Can Induce the Arsenite-Resistance Mutant PML Protein Solubility ChangesArsenic metabolism and thioarsenicals.Double-edged effects of arsenic compounds: anticancer and carcinogenic effects.The combination of arsenic and cryptotanshinone induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in breast cancer cells.Involvement of endoplasmic reticulum stress in all-trans-retinal-induced retinal pigment epithelium degeneration.Effect of arsenic compounds on the in vitro differentiation of mouse embryonic stem cells into cardiomyocytes.A novel pathway for arsenic elimination: human multidrug resistance protein 4 (MRP4/ABCC4) mediates cellular export of dimethylarsinic acid (DMAV) and the diglutathione conjugate of monomethylarsonous acid (MMAIII).Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.Trivalent methylated arsenic metabolites induce apoptosis in human myeloid leukemic HL-60 cells through generation of reactive oxygen species.Engineering and refolding of a novel trimeric fusion protein TRAIL-collagen XVIII NC1.Comparative toxicity of arsenic metabolites in human bladder cancer EJ-1 cells.Mitochondria are the main target organelle for trivalent monomethylarsonous acid (MMA(III))-induced cytotoxicity.Multidrug resistance protein 1 (ABCC1) confers resistance to arsenic compounds in human myeloid leukemic HL-60 cells.New method and detection of high concentrations of monomethylarsonous acid detected in contaminated groundwater.Assessment of arsenic in colostrum and cord serum and risk exposure to neonates from an island population in China.Reaction mechanism underlying the in vitro transformation of thioarsenicals.Importance of being thiomethylated: formation, fate, and effects of methylated thioarsenicals.Phenylarsine oxide (PAO) induces apoptosis in HepG2 cells via ROS-mediated mitochondria and ER-stress dependent signaling pathways.Formation of dimethylthioarsenicals in red blood cells.Systemic distribution and speciation of diphenylarsinic acid fed to rats.Generation of thioarsenicals is dependent on the enterohepatic circulation in rats.Distribution and speciation of arsenic after intravenous administration of monomethylmonothioarsonic acid in rats.Trivalent arsenicals are bound to proteins during reductive methylationLetter to the editor regarding the article by Dheeman et al., 2014Role of arsenic (+3 oxidation state) methyltransferase in arsenic mediated APL treatment: an in vitro investigationTherapeutic strategy of arsenic trioxide in the fight against cancers and other diseasesRapid identification of specific DNA aptamers precisely targeting CD33 positive leukemia cells through a paired cell-based approachIrreversibility of arsenic trioxide induced PML/RARα fusion protein solubility changesSelection and characterization of novel DNA aptamer against colorectal carcinoma Caco-2 cellsIntegrity of zinc finger motifs in PML protein is necessary for inducing its degradation by antimonyNovel insights into the role of aptamers in the fight against cancerAcute promyelocytic leukemia and variant fusion proteins: PLZF-RARα fusion protein at a glancePhenylarsine Oxide Can Induce Degradation of PLZF-RARα Variant Fusion Protein of Acute Promyelocytic Leukemia
P50
Q28484196-D543A92E-565C-466B-9F92-0805C49F2E7BQ33618916-379A2DBC-3E20-4BF5-A041-7EB7B5D0F3C4Q34330006-C07499CC-9D6A-4AD7-8B72-4A63FE9DAF36Q36413252-A1EF0EFA-1649-4384-AFB2-E63F1916086DQ37392124-44181F4C-E5B6-4AA8-928B-D66EA795F312Q37690635-AFAEC748-0341-43D1-A229-1BD3EA9E847CQ37987437-584C933D-3555-4A3F-95BE-9BE69B402174Q38155876-6850CA39-D956-4EB9-BD21-C58C7B9D69C5Q38938902-143549F5-7873-4541-BDA6-8401E3E9E5DFQ38946467-71C4F5DA-5465-4C12-BFFA-E00BE496704BQ38962160-B0136A13-7918-4A90-9430-95906DCD1B85Q38990821-59444E3B-A828-44E7-98FB-4FBD6920DB89Q39117341-5B5C80B1-401C-4CCC-B17F-6CE49B3F036BQ39185316-CADEB5AF-3115-41E2-A7E6-BD8E0CABC5E6Q39233129-A1F26939-C5FF-4D5B-840F-298823327780Q39495284-68863E96-3CBC-4B7D-ACBA-2A9F329256E0Q39529265-A957013D-1653-49E7-98CF-7BB9283DB834Q42715412-3CCCDE6E-FFE8-49F2-AA38-B8BB9AF35381Q43003358-8E826F3A-1801-4A98-8715-41E3C59CC40AQ46498703-54A1B6FA-802C-4843-857A-C8E02FFE9EF0Q46538949-288FA381-5C64-4829-8E44-51BD215E2C92Q46795764-2A846739-8B7A-482F-9B53-9840308DCDF8Q47918806-63971C88-B2C3-4DAD-AE49-DD4153381ACAQ48011102-E6047BCE-8363-422F-9F54-6613C240A98BQ48020020-B927B217-4AEF-4CCA-BAFC-38A98BEFF730Q50528858-03A2D98F-52AB-483F-A4A4-43FA8AEF70C7Q50571876-45234A65-7D03-4584-BC84-3368267E00B4Q80136936-873A2C81-C27A-4F76-8932-979C6BA800E7Q85935811-9F7A20A3-C752-43B3-8392-D3D60EE67D67Q88723132-1A8BCEBC-FB9B-48DE-B4C8-D281B53473F0Q90259701-EEE8B6F8-4967-43CE-A783-BA7432E9EB21Q90293210-BC28CFB8-6C7A-482C-B1B6-476035A33B86Q91031209-36895B07-A2D3-420F-A89D-0B30044FED0EQ91474008-B0F42713-B4AA-46E5-973D-2EEF65A89FFDQ91952012-A7008A20-99E1-41D5-9582-7BB666CA878AQ92104522-E099F469-A3B6-4772-87F5-43DB18C1F3AEQ92279596-6C88E191-9263-4020-856F-AE1E778A2F03Q92352553-7CF76015-F853-4ED2-BBD0-13B64983BA1E
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Hua Naranmandura
@en
Hua Naranmandura
@nl
type
label
Hua Naranmandura
@en
Hua Naranmandura
@nl
prefLabel
Hua Naranmandura
@en
Hua Naranmandura
@nl
P31
P496
0000-0003-0799-2340